UCB, Inc. Announces Regulatory Filings for Cimzia® (Certolizumab Pegol) to Treat Psoriatic Arthritis and Axial Spondyloarthritis
ATLANTA, Feb. 20, 2013 -- ATLANTA, Feb. 20, 2013 /PRNewswire/ -- UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia® (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA). The regulatory filings for two new indications for certolizumab pegol are now under review by the US FDA and EMA.